Table of Content

1. Key Insights

2. Generalized Anxiety Disorder (GAD): Market Overview at a Glance
2.1. Total Market Share (%) Distribution of GAD in 2017
2.2. Total Market Share (%) Distribution of GAD in 2028

3. Key Summary

4. Epidemiology and Market Methodology

5. Disease Background and Overview: Generalized Anxiety Disorder (GAD)
5.1. Introduction
5.2. Symptoms
5.3. Pathophysiology
5.4. Risk Factors
5.5. Diagnosis

6. Epidemiology and Patient Population: Generalized Anxiety Disorder
6.1. Key Findings
6.2. Total 12-Month Prevalent Cases of Generalized Anxiety Disorder in 7MM
6.3. The United States
6.3.1. Assumptions and Rationale
6.3.2. Total 12-Month Prevalent Cases of Generalized Anxiety Disorder (GAD) in the US
6.3.3. Gender-Specific Cases of Generalized Anxiety Disorder (GAD) in the United States
6.3.4. Age-Specific Cases of Generalized Anxiety Disorder (GAD) in the United States
6.3.5. Severity -Specific Cases of Generalized Anxiety Disorder (GAD) in the United States
6.4. EU5
6.4.1. Assumptions and Rationale
6.5. Germany
6.5.1. Total 12-Month Prevalent Cases of Generalized Anxiety Disorder (GAD) in Germany
6.5.2. Gender-Specific Cases of Generalized Anxiety Disorder (GAD) in Germany
6.5.3. Age-Specific Cases of Generalized Anxiety Disorder (GAD) in Germany
6.5.4. Severity -Specific Cases of Generalized Anxiety Disorder (GAD) in Germany
6.6. France
6.6.1. Total 12-Month Prevalent Cases of Generalized Anxiety Disorder (GAD) in France
6.6.2. Gender-Specific Cases of Generalized Anxiety Disorder (GAD) in France
6.6.3. Age-Specific Cases of Generalized Anxiety Disorder (GAD) in France
6.6.4. Severity -Specific Cases of Generalized Anxiety Disorder (GAD) in France
6.7. Italy
6.7.1. Total 12-Month Prevalent Cases of Generalized Anxiety Disorder (GAD) in Italy
6.7.2. Gender-Specific Cases of Generalized Anxiety Disorder (GAD) in Italy
6.7.3. Age-Specific Cases of Generalized Anxiety Disorder (GAD) in Italy
6.7.4. Severity -Specific Cases of Generalized Anxiety Disorder (GAD) in Italy
6.8. Spain
6.8.1. Total 12-Month Prevalent Cases of Generalized Anxiety Disorder (GAD) in Spain
6.8.2. Gender-Specific Cases of Generalized Anxiety Disorder (GAD) in Spain
6.8.3. Age-Specific Cases of Generalized Anxiety Disorder (GAD) in Spain
6.8.4. Severity -Specific Cases of Generalized Anxiety Disorder (GAD) in Spain
6.9. The United Kingdom (UK)
6.9.1. Total 12-Month Prevalent Cases of Generalized Anxiety Disorder (GAD) in the UK
6.9.2. Gender-Specific Cases of Generalized Anxiety Disorder in the United Kingdom
6.9.3. Age-Specific Cases of Generalized Anxiety Disorder (GAD) in the UK
6.9.4. Severity -Specific Cases of Generalized Anxiety Disorder (GAD) in the UK
6.10. Japan
6.10.1. Assumptions and Rationale
6.10.2. Total 12-Month Prevalent Cases of Generalized Anxiety Disorder (GAD) in Japan
6.10.3. Gender-Specific Cases of Generalized Anxiety Disorder (GAD) in Japan
6.10.4. Age-Specific Cases of Generalized Anxiety Disorder (GAD) in Japan
6.10.5. Severity -Specific Cases of Generalized Anxiety Disorder (GAD) in Japan

7. Current Treatment
7.1. Treatment of special populations
7.2. Treatment Guidelines

8. Unmet Need

9. Case Report
9.1. A Case Report of GAD and Changes in Treatment Plan Based on Patient Care Scenario: Follow up

10. Marketed Drugs
10.1. Key Cross Competition- Key therapies

11. Emerging Drugs
11.1. Key Cross Competition
11.2. Key Cross Competition- Potential therapies
11.3. Troriluzole: BioHaven Pharmaceuticals
11.3.1. Product Description
11.3.2. Other Developmental Activities
11.3.3. Clinical Development
11.3.4. Safety and Efficacy
11.3.5. Product Profile
11.4. Escitalopram: Allergan
11.4.1. Product Description
11.4.2. Other Developmental Activities
11.4.3. Clinical Development
11.4.4. Safety and Efficacy
11.4.5. Product Profile

12. Market Size: Generalized Anxiety Disorder
12.1. Key Findings
12.2. Total Market Size of Generalized Anxiety Disorder in 7MM
12.3. Total Market Size of Generalized Anxiety Disorder by Therapies in 7MM

13. Market Outlook: 7 MM
13.1. United States
13.1.1. The total market size of Generalized Anxiety Disorder in the US
13.1.2. Total Market Size of Generalized Anxiety Disorder by Therapies in the US
13.2. EU5
13.3. Germany
13.3.1. Total Market size of Generalized Anxiety Disorder in Germany
13.3.2. Total Market Size of Generalized Anxiety Disorder by Therapies in Germany
13.4. France
13.4.1. The total market size of Generalized Anxiety Disorder in France
13.4.2. Total Market Size of Generalized Anxiety Disorder by Therapies in France
13.5. Italy
13.5.1. The total market size of Generalized Anxiety Disorder in Italy
13.5.2. Total Market Size of Generalized Anxiety Disorder by Therapies in Italy
13.6. Spain
13.6.1. Total Market size of Generalized Anxiety Disorder in Spain
13.6.2. Total Market Size of Generalized Anxiety Disorder by Therapies in Spain
13.7. United Kingdom
13.7.1. The total market size of Generalized Anxiety Disorder in the UK
13.7.2. Total Market Size of Generalized Anxiety Disorder by Therapies in the UK
13.8. Japan
13.8.1. Total Market size of Generalized Anxiety Disorder in Japan
13.8.2. Total Market Size of Generalized Anxiety Disorder by Therapies in Japan

14. Market Drivers

15. Market Barriers

16. Bibliography

17. Appendix
17.1. Report Methodology

18. DelveInsight Capabilities

19. Disclaimer

20. About DelveInsight



List of Figures


Figure 1: Epidemiology and Market Methodology
Figure 2: Symptoms and Behaviors Associated with Generalized Anxiety Disorder
Figure 3: Etiology of GAD
Figure 4: Total 12-Month Prevalent Cases of Generalized Anxiety Disorder in 7MM (2017–2028)
Figure 5: Total 12-Month Prevalent Cases of Generalized Anxiety Disorder in the US (2017–2028)
Figure 6: Gender-Specific Cases of Generalized Anxiety Disorder in the US (2017–2028)
Figure 7: Age-Specific Cases of Generalized Anxiety Disorder in the US (2017–2028)
Figure 8: Severity-Specific Cases of Generalized Anxiety Disorder in Children and Adolescents in the US (2017–2028)
Figure 9: Severity-Specific Cases of Generalized Anxiety Disorder in Adults in the US (2017–2028)
Figure 10: Total 12-Month Prevalent Cases of Generalized Anxiety Disorder in Germany (2017–2028)
Figure 11: Gender-Specific Cases of Generalized Anxiety Disorder in Germany (2017–2028)
Figure 12: Age-Specific Cases of Generalized Anxiety Disorder in Germany (2017–2028)
Figure 13: Severity-Specific Cases of Generalized Anxiety Disorder in Children and Adolescents in Germany (2017–2028)
Figure 14: Severity-Specific Cases of Generalized Anxiety Disorder in Adults in Germany (2017–2028)
Figure 15: Total 12-Month Prevalent Cases of Generalized Anxiety Disorder in France (2017–2028)
Figure 16: Gender-Specific Cases of Generalized Anxiety Disorder in France (2017–2028)
Figure 17: Age-Specific Cases of Generalized Anxiety Disorder in France (2017–2028)
Figure 18: Severity-Specific Cases of Generalized Anxiety Disorder in Children and Adolescents in France (2017–2028)
Figure 19: Severity-Specific Cases of Generalized Anxiety Disorder in Adults in France (2017–2028)
Figure 20: Total 12-Month Prevalent Cases of Generalized Anxiety Disorder in Italy (2017–2028)
Figure 21: Gender-Specific Cases of Generalized Anxiety Disorder in Italy (2017–2028)
Figure 22: Age-Specific Cases of Generalized Anxiety Disorder in Italy (2017–2028)
Figure 23: Severity-Specific Cases of Generalized Anxiety Disorder in Children and Adolescents in Italy (2017–2028)
Figure 24: Severity-Specific Cases of Generalized Anxiety Disorder in Adults in Italy (2017–2028)
Figure 25: Total 12-Month Prevalent Cases of Generalized Anxiety Disorder in Spain (2017–2028)
Figure 26: Gender-Specific Cases of Generalized Anxiety Disorder in Spain (2017–2028)
Figure 27: Age-Specific Cases of Generalized Anxiety Disorder in Spain (2017–2028)
Figure 28: Severity-Specific Cases of Generalized Anxiety Disorder in Children and Adolescents in Spain (2017–2028)
Figure 29: Severity-Specific Cases of Generalized Anxiety Disorder in Adults in Spain (2017–2028)
Figure 30: Total 12-Month Prevalent Cases of Generalized Anxiety Disorder in the UK (2017–2028)
Figure 31: Gender-Specific Cases of Generalized Anxiety Disorder in the UK (2017–2028)
Figure 32: Age-Specific Cases of Generalized Anxiety Disorder in the UK (2017–2028)
Figure 33: Severity-Specific Cases of Generalized Anxiety Disorder in Children and Adolescents in the UK (2017–2028)
Figure 34: Severity-Specific Cases of Generalized Anxiety Disorder in Adults in the UK (2017–2028)
Figure 35: Total 12-Month Prevalent Cases of Generalized Anxiety Disorder in Japan (2017–2028)
Figure 36: Gender-Specific Cases of Generalized Anxiety Disorder in Japan (2017–2028)
Figure 37: Age-Specific Cases of Generalized Anxiety Disorder in Japan (2017–2028)
Figure 38: Severity-Specific Cases of Generalized Anxiety Disorder in Children and Adolescents in Japan (2017–2028)
Figure 39: Severity-Specific Cases of Generalized Anxiety Disorder in Adults in Japan (2017–2028)
Figure 40: Pharmacotherapy for GAD
Figure 41: Unmet Needs for Generalized anxiety disorder
Figure 42: Total Market Size of Generalized Anxiety Disorder in 7MM in USD Million (2017-2028)
Figure 43: Total Market Size of GAD by Therapies in 7MM in USD Million (2017-2028)
Figure 44: Market size of Generalized Anxiety Disorder in the US (2017–2028)
Figure 45: Total Market Size of GAD by Therapies in the US, in USD Million (2017-2028)
Figure 46: Market size of Generalized Anxiety Disorder in Germany (2017–2028)
Figure 47: Total Market Size of GAD by Therapies in Germany, in USD Million (2017-2028)
Figure 48: Market size of Generalized Anxiety Disorder in France (2017–2028)
Figure 49: Total Market Size of GAD by Therapies in France, in USD Million (2017-2028)
Figure 50: Market size of Generalized Anxiety Disorder in Italy (2017–2028)
Figure 51: Total Market Size of GAD by Therapies in Italy, in USD Million (2017-2028)
Figure 52: Market size of Generalized Anxiety Disorder in Spain (2017–2028)
Figure 53: Total Market Size of GAD by Therapies in Spain, in USD Million (2017-2028)
Figure 54: Market size of Generalized Anxiety Disorder in the UK (2017–2028)
Figure 55: Total Market Size of GAD by Therapies in the UK, in USD Million (2017-2028)
Figure 56: Market size of Generalized Anxiety Disorder in Japan (2017–2028)
Figure 57: Total Market Size of GAD by Therapies in Japan, in USD Million (2017-2028)
Figure 58: Market Drivers of Generalized anxiety disorder
Figure 59: Market Barriers to Generalized anxiety disorder


List of Tables


Table 1: Medical Conditions and Medications That Can Cause Anxiety
Table 2: Characteristics to define Generalized anxiety disorder in DSM-V
Table 3: Evolution of the definition of Generalized Anxiety Disorder in succeeding editions of the DSM and ICD
Table 4: Total 12-Month Prevalent Cases of Generalized Anxiety Disorder in 7MM (2017–2028)
Table 5: Total 12-Month Prevalent Cases of Generalized Anxiety Disorder in the US (2017–2028)
Table 6: Gender-Specific Cases of Generalized Anxiety Disorder in the US (2017–2028)
Table 7: Age-Specific Cases of Generalized Anxiety Disorder in the US (2017–2028)
Table 8: Severity-Specific Cases of Generalized Anxiety Disorder in Children and Adolescents in the US (2017–2028)
Table 9: Severity-Specific Cases of Generalized Anxiety Disorder in Adults in the US (2017–2028)
Table 10: Total 12-Month Prevalent Cases of Generalized Anxiety Disorder in Germany (2017–2028)
Table 11: Gender-Specific Cases of Generalized Anxiety Disorder in Germany (2017–2028)
Table 12: Age-Specific Cases of Generalized Anxiety Disorder in Germany (2017–2028)
Table 13: Severity-Specific Cases of Generalized Anxiety Disorder in Children and Adolescents in Germany (2017–2028)
Table 14: Severity-Specific Cases of Generalized Anxiety Disorder in Adults in Germany (2017–2028)
Table 15: Total 12-Month Prevalent Cases of Generalized Anxiety Disorder in France (2017–2028)
Table 16: Gender-Specific Cases of Generalized Anxiety Disorder in France (2017–2028)
Table 17: Age-Specific Cases of Generalized Anxiety Disorder in France (2017–2028)
Table 18: Severity-Specific Cases of Generalized Anxiety Disorder in Children and Adolescents in France (2017–2028)
Table 19: Severity-Specific Cases of Generalized Anxiety Disorder in Adults in France (2017–2028)
Table 20: Total 12-Month Prevalent Cases of Generalized Anxiety Disorder in Italy (2017–2028)
Table 21: Gender-Specific Cases of Generalized Anxiety Disorder in Italy (2017–2028)
Table 22: Age-Specific Cases of Generalized Anxiety Disorder in Italy (2017–2028)
Table 23: Severity-Specific Cases of Generalized Anxiety Disorder in Children and Adolescents in Italy (2017–2028)
Table 24: Severity-Specific Cases of Generalized Anxiety Disorder in Adults in Italy (2017–2028)
Table 25: Total 12-Month Prevalent Cases of Generalized Anxiety Disorder in Spain (2017–2028)
Table 26: Gender-Specific Cases of Generalized Anxiety Disorder in Spain (2017–2028)
Table 27: Age-Specific Cases of Generalized Anxiety Disorder in Spain (2017–2028)
Table 28: Severity-Specific Cases of Generalized Anxiety Disorder in Children and Adolescents in Spain (2017–2028)
Table 29: Severity-Specific Cases of Generalized Anxiety Disorder in Adults in Spain (2017–2028)
Table 30: Total 12-Month Prevalent Cases of Generalized Anxiety Disorder in the UK (2017–2028)
Table 31: Gender-Specific Cases of Generalized Anxiety Disorder in the UK (2017–2028)
Table 32: Age-Specific Cases of Generalized Anxiety Disorder in the UK (2017–2028)
Table 33: Severity-Specific Cases of Generalized Anxiety Disorder in Children and Adolescents in the UK (2017–2028)
Table 34: Severity-Specific Cases of Generalized Anxiety Disorder in Adults in the UK (2017–2028)
Table 35: Total 12-Month Prevalent Cases of Generalized Anxiety Disorder in Japan (2017–2028)
Table 36: Gender-Specific Cases of Generalized Anxiety Disorder in Japan (2017–2028)
Table 37: Age-Specific Cases of Generalized Anxiety Disorder in Japan (2017–2028)
Table 38: Severity-Specific Cases of Generalized Anxiety Disorder in Children and Adolescents in Japan (2017–2028)
Table 39: Severity-Specific Cases of Generalized Anxiety Disorder in Adults in Japan (2017–2028)
Table 40: Treatment Approach to GAD
Table 41: Treatment Recommendations
Table 42: Marketed Drugs Analysis- Key cross
Table 43: Emerging Drugs Analysis-Key therapies
Table 44: Emerging Drugs Analysis- Potential therapies
Table 45: Troriluzole, Clinical Trial Description, 2019
Table 46: Escitalopram, Clinical Trial Description, 2019
Table 47: Total Market Size of Generalized Anxiety Disorder in 7MM in USD Million (2017-2028)
Table 48: Total Market Size of GAD by Therapies in 7MM in USD Million (2017-2028)
Table 49: Total Market size of Generalized Anxiety Disorder in the US (2017–2028)
Table 50: Total Market Size of GAD by Therapies in the US in USD Million (2017-2028)
Table 51: Total Market size of Generalized Anxiety Disorder in Germany (2017–2028)
Table 52: Total Market Size of GAD by Therapies in Germany in USD Million (2017-2028)
Table 53: Total Market size of Generalized Anxiety Disorder in France (2017–2028)
Table 54: Total Market Size of GAD by Therapies in France in USD Million (2017-2028)
Table 55: Total Market size of Generalized Anxiety Disorder in Italy (2017–2028)
Table 56: Total Market Size of GAD by Therapies in Italy in USD Million (2017-2028)
Table 57: Total Market size of Generalized Anxiety Disorder in Spain (2017–2028)
Table 58: Total Market Size of GAD by Therapies in Spain in USD Million (2017-2028)
Table 59: Total Market size of Generalized Anxiety Disorder in the UK (2017–2028)
Table 60: Total Market Size of GAD by Therapies in the UK in USD Million (2017-2028)
Table 61: Total Market size of Generalized Anxiety Disorder in Japan (2017–2028)
Table 62: Total Market Size of GAD by Therapies in Japan in USD Million (2017-2028)